Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | market report
United Arab Emirates Pharmaceuticals and Healthcare Report Q4 2008 (Business Monitor International)
- Market: Healthcare and Medical
- Published Date: 07/11/2008
- Report Title: United Arab Emirates Pharmaceuticals and Healthcare Report Q4 2008
- Table of Contents: View Table of Contents
- Report Type: Market Report
- Country: United Arab Emirates
- Number of Pages: 91
BMI estimates that the United Arab Emirates’ (UAE) drug market expenditure was AED2.71bn (US$0.74bn) in 2007. Over the forecast period (2008-2012), we expect growth to average 8.8% year-onyear (y-o-y), with the market reaching a value of AED4.13bn (US$1.12bn) by the end of 2012.
Over the next five years, there are likely to be major structural changes in the way in which healthcare is provided in the UAE. Duabi and Abu Dhabi have already unveiled universal health insurance models during 2008, and the Ministry of Health is hoping to announce a system which includes the whole of the UAE in the near future.
In BMI’s updated Business Environment Rankings for the Middle East and Africa, the UAE remains top of the table by some distance of 15 regional markets surveyed. Although its drug expenditure is notably lower than that of Saudi Arabia, the UAE drug market’s high growth potential and the stable regulatory and political environment offer a favourable business location. This view continues to be born out, with US-based Pfizer becoming the latest multinational drugmaker to choose the UAE as its regional headquarters.
Exchange rates have caused problems in the UAE’s import reliant drug market. In response to the weak dirham against the euro, the UAE's Ministry of Health announced that the prices of medicines imported from eurozone countries will be increased, with effect from October 15. The price of drugs to treat chronic diseases will increase by 5.85% and the price of non-chronic disease medicines will increase by 21.4%; prices will be reviewed again in two years time. Import prices will continue to be calculated by considering the price of the drug in the country of origin and in comparable neighbouring countries, and the pricing calculation will also be reviewed every two years.
While most of the UAE’s pharmaceutical needs are supplied by imports, the country’s domestic pharmaceutical industy continues to expand its international footprint. Gulf Pharmaceutical Industries (Julphar) is set to open a number of international plants. Manufacturing operations in Afghanistan are scheduled to begin in late 2008; plants in Sudan and Morocco should open in 2009; and plants in Yemen, Iran and Lebanon should open in 2010. Meanwhile, Globalpharma recently received good manufacturing practice (GMP) certification from South Africa’s Medicines Control Council (MCC).
Over the next five years, there are likely to be major structural changes in the way in which healthcare is provided in the UAE. Duabi and Abu Dhabi have already unveiled universal health insurance models during 2008, and the Ministry of Health is hoping to announce a system which includes the whole of the UAE in the near future.
In BMI’s updated Business Environment Rankings for the Middle East and Africa, the UAE remains top of the table by some distance of 15 regional markets surveyed. Although its drug expenditure is notably lower than that of Saudi Arabia, the UAE drug market’s high growth potential and the stable regulatory and political environment offer a favourable business location. This view continues to be born out, with US-based Pfizer becoming the latest multinational drugmaker to choose the UAE as its regional headquarters.
Exchange rates have caused problems in the UAE’s import reliant drug market. In response to the weak dirham against the euro, the UAE's Ministry of Health announced that the prices of medicines imported from eurozone countries will be increased, with effect from October 15. The price of drugs to treat chronic diseases will increase by 5.85% and the price of non-chronic disease medicines will increase by 21.4%; prices will be reviewed again in two years time. Import prices will continue to be calculated by considering the price of the drug in the country of origin and in comparable neighbouring countries, and the pricing calculation will also be reviewed every two years.
While most of the UAE’s pharmaceutical needs are supplied by imports, the country’s domestic pharmaceutical industy continues to expand its international footprint. Gulf Pharmaceutical Industries (Julphar) is set to open a number of international plants. Manufacturing operations in Afghanistan are scheduled to begin in late 2008; plants in Sudan and Morocco should open in 2009; and plants in Yemen, Iran and Lebanon should open in 2010. Meanwhile, Globalpharma recently received good manufacturing practice (GMP) certification from South Africa’s Medicines Control Council (MCC).
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
